IRCT20200404046938N1
Not yet recruiting
Phase 3
Comparison of the effectiveness of oxytocin nasal spray with placebo on symptoms and treatment of adults with autism: a randomized clinical trial
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Autistic Disorder.
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 40
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age between 16 years and zero months to 55 years and 11 months
- •Confirmation of diagnosis by a psychiatrist based on dsm5
- •Complete physical examination and normal laboratory tests
- •Ability to understand and speak Persian fluently
- •Ability to read and understand the consent form in full and if it is not possible for the legal guardian to read and sign the form
- •Clinical global impression\-severity CGI\-S score above 4 in screening
- •Intelligence score in Stanford test \- above 75
Exclusion Criteria
- •Patients with nasal septal deformity and previous epithelial injuries and a history of nasal surgeries with a risk of nasal epithelium damage and people with a history of inhaled substance use
- •Patients with nasal congestion due to colds
- •Patients in the acute phase of psychiatric illness or with thoughts of death and suicide
- •Having a history of neurological diseases, seizures and head injuries
- •People with a history of neurological or metabolic disease that affects their sensory and motor function, etc.
- •Receive stimulant medications
- •History of uncontrolled cardiovascular, renal and hepatic diseases
- •Pregnant women or young women who do not take oral contraceptives
- •People whose type and dose of psychiatric medication have changed in the last 4 weeks
- •People with a history of chronic oxytocin treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Oxytocin intranasal administrations in children with Prader-Willi syndrome aged from 3 to 12 years.EUCTR2016-003273-18-FRniversity Hospital of Toulouse40
Not yet recruiting
Phase 2
Oxytocin & benzodiazepines2024-516262-11-00St. Olavs Hospital HF60
Recruiting
Phase 3
Evaluation of nasal oxytocin spray efficacy in cutting methadone in opioids addicted people that have received methadone .drug addiction.Mental and behavioural disorders due to use of opioidsIRCT20191003044971N1Tehran University of Medical Sciences60
Active, not recruiting
Not Applicable
Effects of intranasal application of oxytocin on empathy and mentalising in patients with psychotic disorders and severe personality disordersEUCTR2007-006561-32-DEWL University Hospital Bochum
Not yet recruiting
Phase 3
The efficacy of intranasal oxytocin before applied behavior analysis (ABA) therapy with autistic spectrum disorderIRCT20211004052670N1Esfahan University of Medical Sciences70